Wordt geladen...

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

PURPOSE: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Ther
Hoofdauteurs: Mahoney, Kathleen M., Freeman, Gordon J., McDermott, David F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497957/
https://ncbi.nlm.nih.gov/pubmed/25823918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.02.018
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!